| Literature DB >> 32283156 |
Lei Huang1, Xiuwen Zhang2, Xinyue Zhang3, Zhijian Wei4, Lingli Zhang5, Jingjing Xu5, Peipei Liang6, Yuanhong Xu7, Chengyuan Zhang8, Aman Xu9.
Abstract
BACKGROUND: The outbreak of coronavirus-disease-2019 (COVID-19) has rapidly spread to many places outside Wuhan. Previous studies on COVID-19 mostly included older hospitalized-adults. Little information on infectivity among and characteristics of youngsters with COVID-19 is available.Entities:
Keywords: COVID-19; Characteristics; Cluster of youngsters; Incubation period; Infectivity; Outside Wuhan; Prospective contact-tracing study; Rapid transmission
Mesh:
Year: 2020 PMID: 32283156 PMCID: PMC7194554 DOI: 10.1016/j.jinf.2020.03.006
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 6.072
Demographic and baseline characteristics of the eight young patients with confirmed 2019 novel coronavirus disease as of February 17, 2020
| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Summary |
|---|---|---|---|---|---|---|---|---|---|
| Relationship with Patient 1 | Index | Younger cousin | Previous classmate | Previous classmate | Previous classmate | Previous classmate | Previous classmate | Previous classmate | - |
| Age (years) | 22 | 16 | 22 | 22 | 22 | 21 | 21 | 23 | 22 (16-23) |
| Male sex | Y | N | Y | Y | N | Y | Y | Y | 6/8 (75%) |
| Height (cm) | 170 | 167 | 180 | 175 | 160 | 170 | 180 | 180 | 173 (160-180) |
| Weight (kg) | 82 | 60 | 77 | 65 | 48 | 85 | 70 | 85 | 74 (48-85) |
| Body mass index (kg/m2) | 21.5 | 23.8 | 21.2 | 18.6 | 21.6 | 22.7 (18.6–29.4) | |||
| Current smoker | N | N | N | Y | N | N | N | Y | 2/8 (25%) |
| Comorbidity | None | None | None | None | Chronic gastritis | Fatty liver | Chronic gastritis | None | - |
| Travel to or passage through Wuhan or other potential epidemic places | Y (Wuhan) | N | N | N | N | N | N | N | 1/8 (13%) |
| Days from exposure to illness onset | ≥ 4 | 3 or 7 | 3 | 1 | 4 | 2 | 2 | 1 | 2 (1-4) |
| Days of serial interval | - | 4 | 2 | 0 | 3 | 1 | 1 | 0 | 1 (0-4) |
| Days from illness onset to first admission | 2 | 1 | 2 | 3 | 2 | 3 | 2 | 3 | 2 (1-3) |
| Days from admission of Patient 1 to admission of the underlying patient | - | 3 | 2 | 1 | 3 | 2 | 1 | 1 | 2 (1-3) |
| Days from illness onset to first respiratory sample collection | 4 | 1 | 2 | 4 | 2 | 3 | 2 | 3 | 3 (1-4) |
| Days from illness onset to first blood sample collection | 4 | 2 | 2 | 4 | 3 | 5 | 2 | 3 | 3 (2-5) |
| Days from illness onset to first positive rRT-PCR test for SARS-CoV-2 | 4 | 1 | 2 | 4 | 2 | 3 | 2 | 3 | 3 (1-4) |
| Days from illness onset to diagnosis by two positive rRT-PCR tests for SARS-CoV-2 | 5 | 2 | 3 | 5 | 3 | 4 | 3 | 4 | 4 (2-5) |
| Days from first admission to transfer | 5 | 3 | 3 | 4 | 3 | 2 | - | - | 3 (2-5) |
| Days from first admission to discharge | - | 16 | 18 | - | - | - | 21 | 17 | 18 (16-21) |
Described for continuous and categorical variables, and expressed as median (range) and count/total number of patients with available data (percentage), respectively.
For Patients 3-8.
For Patients 2-8.
For Patients 1-6; the other patients have not been transferred.
For Patients 2, 3, and 8; the other patients remain in hospital. Values shown in bold indicate abnormal ones. ↑, above the upper limit of the normal range; ↓, below the lower limit of the normal range; -, not applicable; Y, Yes; N, No; rRT-PCR, real-time reverse-transcriptase polymerase-chain-reaction.
Fig. 1Representative transverse chest computed tomography scan images. (A) Day 1 after illness onset for Patient Index. A few infiltrates (slight slice-like shadow with increased density) in the lower lobe of the right lung were seen. (B) Day 3 after illness onset for Patient Index. In the peripheral zones of both lungs, scattered ground-glass opacities with fuzzy edges were seen, suggesting bilateral pneumonia with highly likely viral nature. (C) Day 2 after illness onset for Patient 3. A few infiltrates and ground-glass opacities were detected in the lower lobe of left lung. (D) Day 3 after illness onset for Patient 4. Ground-glass opacities and infiltrates in the right lung were observed. (E) Day 2 after illness onset for Patient 7. Small patchy and mottling high-density sub-pleural shadows were seen in the upper lobe of left lung. (F) Day 5 after illness onset for Patient 7. The left upper lung lesion progressed. Antiviral therapy started. (G) Day 13 after illness onset for Patient 7. Patchy blurring infiltrates in the peripheral parts of the left lung with obscure boundary remained. (H) Day 21 after illness onset for Patient 7. The patchy ground-glass density shadows and infiltrates with fuzzy edges in the left lung had been obviously absorbed. (I) Day 3 after illness onset for Patient 8. Few strip-like shadows with uneven density were seen in both lungs. (J) Day 6 after illness onset for Patient 8. Multifocal ground-glass density shadows and opacities in the peripheral parts of both lungs were observed. Antiviral therapy started. (K) Day 14 after illness onset for Patient 8. The multiple patchy high-density shadows consistent with novel coronavirus pneumonia with unclear boundary seen in the peripheral parts of both lungs progressed. (K) Day 18 after illness onset for Patient 8. Absorption of pneumonia lesions in both lungs was observed compared to the previous scan.
Symptoms, signs, radiological findings, treatment, and outcomes of the young cluster infected with the 2019 novel coronavirus disease.
| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Summary |
|---|---|---|---|---|---|---|---|---|---|
| Fever | Y1 (3 d) | Y1 (2 d) | Y (1 d) | Y1 (3 d) | Y1 (3 d) | N | Y1 (2 d) | Y1 (4 d) | 6; 7, 3 (1-4); 0, 0 |
| Body temperature on admission (°C) | 38.0 | 37.2 | 37.0 | 37.6 | 38.2 | 37.0 | 37.4 | 37.7 | 37.5 (37.0-38.2) |
| Highest body temperature (°C) | 38.4 | 38.5 | 37.7 | 38.5 | 38.2 | 37.1 | 38.0 | 38.9 | 38.5 (37.1-38.9) |
| Intermittent fever | Y | Y | N | N | Y | N | N | N | 3/8 (38%) |
| With chills | N | N | Y | Y | Y | N | N | N | 3/8 (38%) |
| Fatigue | N | N | Y1 (3 d) | Y (1 d) | N | Y1 (2 d) | Y (3 d) | 2; 4, 3 (1-3); 1, 0 | |
| Myalgia | Y (2 d) | N | Y1 (3 d) | N | N | N | Y (2 d) | 1; 3, 2 (2-3); 1, 0 | |
| Cough | Y (2 d) | N | Y1 (3 d) | Y (2 d) | Y1 (4 d) | Y1 (2 d) | Y (3 d) | 3; 6, 3 (2-4); 1, 0 | |
| Sputum production | Y (2 d) | N | Y (1 d) | Y (2 d) | N | N | N | Y (3 d) | 0; 4, 2 (1-3); 0, 0 |
| Hemoptysis | N | N | N | N | N | N | N | 0; 0; 1, 0 | |
| Sore throat | N | N | Y1 (3 d) | N | Y1 (3 d) | N | N | Y1 (4 d) | 3; 3, 3 (3-4); 0, 0 |
| Nasal congestion | Y1 (3 d) | N | Y (1 d) | Y (3 d) | Y (2 d) | N | Y1 (4 d) | 2; 5, 3 (1-4); 1, 0 | |
| Rhinorrhea | Y1 (3 d) | N | N | N | Y (2 d) | N | Y1 (4 d) | 2; 3, 3 (2-4); 1, 0 | |
| Sneezing | N | Y (2 d) | N | Y (1 d) | N | Y (2 d) | 0; 3, 2 (1-2); 2, 0 | ||
| Shortness of breath | N | N | N | N | Y1 (2 d) | N | 1; 1, 2 (2-2); 2, 1 | ||
| Chest discomfort | N | N | N | 0; 0; 5, 2 | |||||
| Chest pain | N | N | N | N | N | N | 0; 0; 2, 0 | ||
| Headache | N | Y (1 d) | N | Y (1 d) | Y (2 d) | N | N | N | 0; 3, 1 (1-2); 0, 0 |
| Dizziness | Y1 (2 d) | N | N | N | N | N | N | N | 1; 1, 2 (2-2); 0, 0 |
| Eye discomfort | Y1 (3 d) | N | Y (2 d) | N | N | N | N | N | 1; 2, 3 (2-3); 0, 0 |
| Backache | N | N | Y1 (3 d) | N | N | N | N | N | 1; 1, 3 (3-3); 0, 0 |
| Anorexia | N | N | N | N | Y (1 d) | Y (1 d) | N | 0; 2, 1 (1-1); 1, 0 | |
| Nausea | N | Y (1 d) | Y (1 d) | N | Y (1 d) | 0; 3, 1 (1-1); 3, 1 | |||
| Vomiting | N | N | N | N | 0; 0; 4, 3 | ||||
| Diarrhea | N | N | Y (up to 3 times/d, 3 d) | 0; 1, 3 (3-3); 5, 3 | |||||
| Abdominal discomfort | N | N | N | Y (1 d) | N | N | N | 0; 1, 1; 1, 0 | |
| ≥2 upper respiratory infection symptoms before/on admission | Y | N | Y | Y | N | Y | N | Y | 5/8 (63%) |
| ≥1 digestive symptom before/on admission | N | N | N | N | Y | Y | N | Y | 3/8 (38%) |
| Both fever and cough before/on admission | Y | N | Y | Y | N | N | Y | Y | 5/8 (63%) |
| No. of symptoms on illness onset | 5 | 1 | 5 | 1 | 2 | 1 | 4 | 4 | 3 (1-5) |
| No. of symptoms before/on admission | 8 | 2 | 9 | 7 | 6 | 6 | 4 | 11 | 6 (2-11) |
| Respiratory rate on admission (breaths/min) | 20 | 20 | 20 | 18 | 18 | 18 | 20 | 20 (18-22) | |
| Oximetry saturation on admission (%) | 97 | 97 | 98 | 97 | 96 | 97 | 98 | 98 | 97 (96-98) |
| Heart rate on admission (beats/min) | 86 | 82 | 90 | 90 | 94 | 86 | 94 | 92 | 90 (82-94) |
| Systolic pressure on admission (mm Hg) | 120 | 120 | 125 | 131 | 124 | 120 | 118 | 122 (118-150) | |
| Diastolic pressure on admission (mm Hg) | 80 | 74 | 76 | 89 | 78 | 74 | 75 | 77 (74-94) | |
| Pneumonia | Y (mild) | N | Y (mild) | Y (mild) | N | Y (mild) | Y (mild) | Y (mild) | 6/8 (75%) |
| Multifocal mottling, patchy shadows, and/or ground-glass opacities | Y | N | Y | Y | N | Y | Y | Y | 6/8 (75%) |
| Location of pneumonia | Lower lobe of right lung | - | Lower lobe of left lung | Middle and lower lobes of right lung | - | Lower lobe of right lung | Lower lobe of right lung | Middle lobe of both lungs | - |
| Bilateral lung involvement | N | - | N | N | - | N | N | Y | 1/6 (17%) |
| Recombinant human interferon | Y (α-1b; α-2b) | Y (α-1b) | Y (α-1b; α-2b) | Y (α-1b; α-2b) | Y (α-1b) | N | Y | Y | 7/8 (88%) |
| Lopinavir | Y | N | Y | Y | Y | Y | Y | Y | 7/8 (88%) |
| Ritonavir | Y | N | Y | Y | Y | Y | Y | Y | 7/8 (88%) |
| Other antiviral therapy | Y (adenosine monophosphate) | Y (ribavirin; oseltamivir) | N | N | N | N | Y (arbidol; ribavirin) | N | 3/8 (38%) |
| Any antiviral therapy | Y | Y | Y | Y | Y | Y | Y | Y | 8/8 (100%) |
| Levofloxacin | Y | N | Y | Y | N | N | N | N | 4/8 (50%) |
| Moxifloxacin | N | Y | N | N | Y | Y | N | Y | 3/8 (38%) |
| Other antibiotic therapy | N | N | N | Y (ceftazidime) | N | N | N | N | 1/8 (13%) |
| Any antibiotic therapy | Y | Y | Y | Y | Y | Y | N | Y | 7/8 (88%) |
| Recovered | N | Y | Y | N | N | N | Y | Y | 4/8 (50%) |
| Discharged | N | Y | Y | N | N | N | Y | Y | 4/8 (50%) |
For symptom variables, it is shown as: number of patients with the symptom presenting on date of illness onset; number of patients with the symptom presenting before or on date of hospital admission, median (range) of the days from onset of the symptom to admission; number of patients with the symptom presenting after admission; number of patients with the symptom whose association with drug use could not be excluded; for the other variables, it is described for continuous and categorical variables, and expressed as median (range) and count/total number of patients with available data (percentage), respectively.
-, not applicable; ↑, above the upper limit of the normal range; ↓, below the lower limit of the normal range; Y, Yes (symptom developed before or on admission; days from onset of the symptom through admission are shown in brackets); Y1, Yes (symptom developed on date of illness onset; days from onset of the symptom through admission are shown in brackets); Y, Yes (symptom developed after admission); Y!, (symptom developed after admission; association with drug use could not be excluded).
Laboratory findings of the young cluster with the 2019 novel coronavirus disease, on admission to hospital1.
| Measure | Reference range | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 7 | Patient 8 | Summary |
|---|---|---|---|---|---|---|---|---|---|
| FDCPH; FAHAMU | FDCPH | FDCPH | FDCPH | FDCPH | FDCPH | FAHAMU | FAHAMU | - | |
| White blood cell count (× 109 cells/L) | 4.00-10.00; 3.50-9.50 | 4.77 | 5.26 | 4.02 | 7.79 | 9.48 | ↓, 2/7 (29%) | ||
| Absolute neutrophil count (× 109 cells/L) | 2.00-7.00; 1.80-6.30 | 3.10 | 3.60 | 2.10 | 6.64 | ↓, 2/7 (29%); ↑, 1/7 (14%) | |||
| Absolute lymphocyte count (× 109 cells/L) | 0.84-4.00; 1.10-3.20 | 1.23 | 1.27 | 1.04 | 1.75 | 1.46 | ↓, 2/7 (29%) | ||
| Red blood cell count (× 1012 cells/L) | 3.50-5.50; 4.30-5.80 | 4.71 | 4.91 | 4.32 | 5.20 | 5.20 | ↑, 2/7 (29%) | ||
| Hemoglobin (g/L) | 110-160; 130-175 | 132 | 151 | 125 | 152 | 159 | ↑, 2/7 (29%) | ||
| Hematocrit (%) | 37.0-50.0; 40.0-50.0 | 49.3 | 42.4 | 49.2 | 45.5 | 38.5 | 46.6 | 46.8 | AN |
| Platelet count (× 109 cells/L) | 100-300; 125-350 | 217 | 209 | 218 | 132 | 246 | 165 | 219 | AN |
| Prothrombin time (sec) | 10.5-14.5; 11.0-16.0 | 10.9 | 11.2 | 12.0 | 11.7 | 13.9 | 15.0 | ↓, 1/7 (14%) | |
| Activated partial thromboplastin time (sec) | 20.0-40.0; 28.0-42.0 | 26.0 | 21.8 | 28.4 | 25.4 | 40.5 | 39.5 | ↑, 1/7 (14%) | |
| International normalized ratio | 0.80-1.20; 0.85-1.15 | 0.94 | 0.89 | 0.96 | 1.04 | 1.01 | 1.06 | ↑, 1/7 (14%) | |
| Fibrinogen (g/L) | 2.00-4.00; 2.00-4.00 | 3.76 | 2.38 | 2.95 | 2.59 | 2.41 | 3.83 | 3.47 | AN |
| D-dimer (μg/L) | 0.00-0.55; 0.00-0.50 | - | - | - | 0.19 | 0.19 | 0.20 | 0.27 | AN |
| Total protein (g/L) | 65.0-85.0; 63.0-82.0 | 80.9 | 65.6 | 78.0 | 65.6 | 69.4 | 71.2 | 82.0 | AN |
| Albumin (g/L) | 40.0-55.0; 35.0-50.0 | 53.6 | 43.4 | 53.3 | 40.4 | 42.8 | 45.5 | 47.2 | AN |
| Pre-albumin (mg/L) | 200-400; - | 261 | 281 | 257 | - | - | ↓, 2/5 (40%) | ||
| Alanine aminotransferase (U/L) | 5-50; 21-72 | 30 | 14 | 20 | 12 | 11 | 27 | ↓, 1/7 (14%) | |
| Aspartate aminotransferase (U/L) | 13-40; 17-59 | 29 | 22 | 24 | 16 | 18 | 24 | 29 | AN |
| Alkaline phosphatase (U/L) | 40-130; 38-126 | 84 | 79 | 104 | 78 | 71 | 51 | 78 | AN |
| Total bilirubin (μmol/L) | 5.0-20.0; 3.0-22.0 | 9.0 | 7.4 | 10.5 | 7.8 | 12.2 | 12.2 | ↑, 1/7 (14%) | |
| Direct bilirubin (μmol/L) | 0.0-7.0; - | 2.1 | 1.6 | 2.1 | 2.1 | 3.2 | - | - | AN |
| Serum creatinine (μmol/L) | 44.0-106.0; 58.0-110.0 | 69.0 | 69.6 | 69.6 | 83.9 | 57.7 | 78.8 | 104.5 | AN |
| Blood urea nitrogen (mmol/L) | 2.76-8.07; 3.20-7.10 | 4.79 | 3.84 | 5.19 | 3.07 | 3.51 | 4.10 | 4.80 | AN |
| Creatine kinase (U/L) | 38-174; 55-170 | 95 | 58 | 104 | 74 | 66 | ↓, 1/7 (14%); ↑, 1/7 (14%) | ||
| Lactate dehydrogenase (U/L) | 110-240; - | 224 | 163 | 240 | 111 | 151 | - | - | AN |
| Hypersensitive troponin I (ng/mL) | -; 0.000-0.034 | - | - | - | - | - | 0.01 | 0.01 | AN |
| Myoglobin (ng/mL) | -; 10-46 | - | - | - | - | - | 14 | ↓, 1/2 (50%) | |
| Potassium (mmol/L) | 3.50-5.30; 3.50-5.10 | 4.88 | 4.50 | 4.44 | 4.68 | 4.08 | 4.16 | 4.17 | AN |
| Sodium (mmol/L) | 137.0-147.0; 137.0-145.0 | 141.2 | 140.4 | 140.9 | 141.5 | 141.8 | 138.8 | 137.4 | AN |
| Calcium (mmol/L) | 2.15-2.75; 2.10-2.55 | 2.40 | 2.23 | 2.38 | 2.23 | 2.28 | 2.40 | 2.33 | AN |
| Chloride (mmol/L) | 96.0-110.0; 98.0-107.0 | 107.6 | 101.0 | 103.9 | 103.0 | 101.5 | 101.3 | ↓, 1/7 (14%) | |
| C-reactive protein (mg/L) | 0.00-7.44; 0.00-10.00 | - | 4.61 | 2.59 | 6.18 | 2.65 | 1.04 | ↑, 1/6 (17%) | |
| Procalcitonin (ng/mL) | 0.000-0.046; 0.000-0.050 | < 0.010 | 0.032 | < 0.010 | 0.039 | - | 0.05 | ↑, 1/6 (17%) | |
| Erythrocyte sedimentation rate (mm/h) | 0-15; - | - | 6 | 7 | - | - | ↑, 1/4 (25%) |
Laboratory findings for Patient 6 whose blood was initially examined in the Hefei City Infectious Disease Hospital have not been obtained.
Summary data are count/total number of patients with available data (percentage) for abnormal values.
-, not available; ↑, value above the upper limit of the normal range; ↓, value below the lower limit of the normal range; AN, all measured values were within normal range; FDCPH, Feidong County People's Hospital; FAHAMU, First Affiliated Hospital of Anhui Medical University.
Close contacts of the index patient admitted to hospital and testing negative for SARS-CoV-2 on rRT-PCR for at least two times.
| Variable | Contact 1 | Contact 2 | Contact 3 | Contact 4 | Contact 5 | Contact 6 | Contact 7 | Contact 8 | Contact 9 |
|---|---|---|---|---|---|---|---|---|---|
| Relationship with index patient | Uncle | Classmate | Classmate | Classmate | Classmate | Classmate | Classmate | Classmate | Classmate |
| Male sex | Y | N | Y | Y | Y | Y | Y | Y | Y |
| Age (years) | 43 | 23 | 23 | 21 | 23 | 21 | 23 | 23 | 24 |
| Current smoker | Y | N | N | N | N | N | N | N | N |
| Date of exposure | Jan 19 | Jan 20 | Jan 21 | Jan 21 | Jan 21 | Jan 21 | Jan 21 | Jan 21 | Jan 21 |
| Exposure place | Apartment in Feidong | Hotpot restaurant in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong | Restaurant & Karaoke room with shared toilet in Feidong |
| Description of exposure place | Confined room without air conditioning | Room with air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning | Room with window open and air conditioning |
| Exposure duration | 1.5 h | 1 h | 5 h | 5 h | 5 h | 5 h | 5 h | 5 h | 5 h |
| Fever | Y (0.5 d; Jan 27; subjective) | Y (0.5 d; Jan 26) | N | N | N | N | N | N | Y (5 h; Jan 26) |
| Body temperature on admission (°C) | 36.6 | 36.6 | 36.7 | 36.2 | 36.8 | 36.7 | 36.6 | 36.7 | 36.5 |
| Highest body temperature (°C) | - | 37.6 (Jan 26; self-measured) | - | - | - | - | - | - | 37.3 (Jan 26; self-measured) |
| Respiratory rate (breaths/min) | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 19 | 18 |
| Oximetry saturation (%) | 98 | 97 | 97 | 97 | 97 | 97 | 96 | 98 | 98 |
| Heart rate (beats/min) | 80 | 80 | 90 | 76 | 78 | 88 | 78 | 99 | 90 |
| Systolic pressure (mm Hg) | 127 | 127 | 140 | 120 | 137 | 115 | 125 | 120 | |
| Diastolic pressure (mm Hg) | 81 | 81 | 80 | 77 | 83 | 84 | 81 | 80 | |
| White blood cell count (× 109 cells/L) | 4.62 | 4.08 | 5.99 | 8.19 | 6.55 | 5.99 | 8.99 | ||
| Neutrophil count (× 109 cells/L) | 2.90 | 3.60 | 5.00 | 3.40 | 3.30 | 4.80 | |||
| Lymphocyte count (× 109 cells/L) | 1.06 | 2.04 | 1.77 | 1.35 | 2.57 | 2.49 | 2.19 | 1.54 | 2.68 |
| Red blood cell count (× 1012 cells/L) | 4.81 | 3.91 | 4.65 | 5.22 | 5.02 | 4.77 | |||
| Hemoglobin (g/dL) | 151.0 | 121.0 | 148.0 | 155.0 | 141.0 | 157.0 | 145.0 | 141.0 | |
| Hematocrit (%) | 45.70 | 49.50 | 43.60 | 47.20 | 44.10 | 48.00 | 45.30 | 43.00 | |
| Platelet count (× 109 cells/L) | 177 | 200 | 219 | 192 | 203 | 234 | 191 | 206 | 226 |
| Prothrombin time (s) | 11.30 | 12.20 | 12.20 | 12.10 | 12.00 | 10.60 | 12.10 | 11.00 | |
| Activated partial thromboplastin time (s) | 23.90 | 28.20 | 30.40 | 34.80 | 26.40 | 26.20 | 25.40 | 22.90 | 25.30 |
| International normalized ratio | 0.97 | 1.05 | 1.05 | 1.04 | 1.04 | 0.91 | 1.04 | 0.95 | |
| Fibrinogen (g/L) | 2.08 | 2.00 | 2.02 | 2.67 | 2.52 | 2.10 | |||
| Total protein (g/L) | 66.1 | 67.2 | - | 69.3 | 74.1 | 75.0 | 76.4 | 72.0 | |
| Albumin (g/L) | 45.5 | 44.1 | - | 46.8 | 48.1 | 48.1 | 44.4 | 46.6 | 49.9 |
| Pre-albumin (mg/L) | 392 | - | 285 | 230 | 245 | 284 | 258 | 317 | |
| Alanine aminotransferase (U/L) | 19 | 6 | - | 9 | 32 | 22 | 43 | 19 | 38 |
| Aspartate aminotransferase (U/L) | 20 | 20 | 34 | 14 | 28 | 21 | 32 | 20 | 28 |
| Alkaline phosphatase (U/L) | 55 | 50 | - | 90 | 93 | 49 | 104 | 52 | 97 |
| Total bilirubin (μmol/L) | 11.3 | 13.6 | - | 12.6 | 18.7 | 14.1 | 11.9 | 9.6 | 5.0 |
| Direct bilirubin (μmol/L) | 1.9 | 2.8 | - | 2.8 | 4.0 | 3.0 | 2.5 | 1.8 | 0.7 |
| Serum creatinine (μmol/L) | 66.5 | 57.3 | 82.3 | 57.6 | 80.4 | 88.1 | 67.6 | 76.5 | 91.9 |
| Blood urea nitrogen (mmol/L) | 3.38 | 2.87 | 4.71 | 4.60 | 5.31 | 6.10 | 5.13 | 6.36 | |
| Creatine kinase (U/L) | 60 | 105 | 64 | 61 | 104 | 59 | 89 | 58 | |
| Lactate dehydrogenase (U/L) | 134 | 136 | 159 | 123 | 149 | 115 | 154 | 144 | 176 |
| Potassium (mmol/L) | 3.94 | 3.82 | 4.76 | 4.01 | 4.19 | 3.96 | 4.27 | 4.76 | |
| Sodium (mmol/L) | 145.5 | 144.7 | 144.1 | 142.4 | 144.7 | 140.7 | 145.1 | 143.3 | 142.8 |
| Calcium (mmol/L) | 2.31 | 2.36 | 2.47 | 2.37 | 2.49 | 2.40 | 2.39 | 2.49 | 2.53 |
| Chloride (mmol/L) | 105.0 | 109.3 | 102.6 | 100.0 | 101.3 | 105.9 | 102.6 | 102.3 | 102.3 |
| C-reactive protein (mg/L) | - | - | 0.60 | 0.31 | 1.67 | - | 0.23 | - | 0.91 |
| Procalcitonin (ng/mL) | 0.044 | 0.046 | 0.039 | - | 0.033 | < 0.01 | |||
| Erythrocyte sedimentation rate (mm/h) | - | 8 | 3 | 4 | 6 | 11 | 8 | 2 | |
| 1st sampling date | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 27 | Jan 28 |
| 1st sampling result | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| 2nd sampling date | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 28 | Jan 29 |
| 2nd sampling result | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| Date of discharged to home isolation | Jan 31 | Feb 1 | Feb 1 | Jan 31 | Jan 31 | Jan 31 | Feb 1 | Jan 31 | Jan 31 |
-, not available; ↑, above normal range; ↓, below normal range; Y, Yes; N, No; rRT-PCR, real-time reverse-transcriptase polymerase-chain-reaction.